Myasthenia gravis: ALG treatment of seriously ill patients

A. Leövey, A. Szobor, G. Y. Szegedi, I. Szathmáry, G. Y. Petrányi

Research output: Contribution to journalArticle

5 Citations (Scopus)


The authors review the theoretical basis of human antilymphocyte globulin (ALG) and human antithymocyte globulin (ATG) treatment in myasthenia gravis. Ten selected seriously ill myasthenic patients were treated with ALG and/or ATG. Three of the patients improved significantly and a further four moderately, whereas the condition of three patients did not change. ALG therapy is effective in the suppression of cellular immune mechanism, therefore it can be assumed that it exerts its effect in myasthenia gravis by inhibiting thymus hormone stimulation.

Original languageEnglish
Pages (from-to)422-432
Number of pages11
JournalEuropean Neurology
Issue number5
Publication statusPublished - Jan 1 1975



  • ALG treatment
  • Antithymocyte globulin
  • Myasthenia gravis
  • Thymus hormone

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Leövey, A., Szobor, A., Szegedi, G. Y., Szathmáry, I., & Petrányi, G. Y. (1975). Myasthenia gravis: ALG treatment of seriously ill patients. European Neurology, 13(5), 422-432.